Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
POSTER: MM-1485 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir Vorobyev, Michèle Cavo, Kazuhito Suzuki, Paweł Robak, Kristin Morris, Chee Paul Lin, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet E. Manasanch, Brandon E. Kremer, MariaVictoria Mateos, Meletios A Dimopoulos (2025). POSTER: MM-1485 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)01371-0.
Article19 days agoMM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir Vorobyev, Michèle Cavo, Kazuhito Suzuki, Paweł Robak, Kristin Morris, Chee Paul Lin, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet E. Manasanch, Brandon E. Kremer, MariaVictoria Mateos, Meletios A Dimopoulos (2025). MM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02742-9.
Article19 days agoDeep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study
Suzanne Trudel, Meral Beksac, Luděk Pour, Sosana Delimpasi, Vladimir Vorobyev, Hang Quach, Ivan Špıčka, Jakub Radocha, Paweł Robak, Kihyun Kım, Michèle Cavo, Kazuhito Suzuki, S. Yousuf Zafar, Ainslee Moore, Michael Duggan, Kristin Morris, Amy Phillips-Jones, Margaret Polinkovsky, Jayleen Grams, Ianire Garrobo-Calleja, Elisabet E. Manasanch, Brandon E. Kremer, Joanna Opalińska, María‐Victoria Mateos, Meletios A Dimopoulos (2025). Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study. , 146(Supplement 1), DOI: https://doi.org/10.1182/blood-2025-2264.
Article19 days agoIsatuximab for the treatment of multiple myeloma: current clinical advances and future directions
Paul G. Richardson, Elisabeth K. O’Donnell, Peter O’Gorman, Lisa Leypoldt, Jacob P. Laubach, Francesca Gay, Xavier Leleu, Thierry Façon, Philippe Moreau, Meletios A Dimopoulos, Hartmut Goldschmidt, K. Elias, Michèle Cavo, Katja Weisel, Jesús G. Berdeja, Robert Z. Orlowski, Meral Beksaç, Aurore Perrot, Joseph Mıkhael, T. John Martin (2025). Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions. , 34(7-8), DOI: https://doi.org/10.1080/13543784.2025.2532446.
Article19 days agoDREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features.
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir Vorobyev, Michèle Cavo, Kazuhito Suzuki, Paweł Robak, Kristin Morris, Chee Paul Lin, Ianire Garrobo-Calleja, Giulia Fulci, Elisabet E. Manasanch, Brandon E. Kremer, María‐Victoria Mateos, Meletios A Dimopoulos (2025). DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7533.
Article19 days ago